BillionToOne, Inc. Class A Common Stock BLLN
Analyst Ratings
- Consensus
- Buy — 6 Buy · 2 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $126.88 (+12.0% upside)
Key Stats
- Today's Range
- $110.42 – $114.02
- 50-Day Range
- $89.78 – $127.72
- 52-Week Range
- $61.96 – $150.44
- Volume
- 468K shs
- Average Volume
- 538K shs
- Market Cap
- $5.35 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.12%
- Days to Cover
- 1.00
About BillionToOne, Inc. Class A Common Stock
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Related Stocks
Compare head-to-head: BLLN vs NTRA·BLLN vs DGX·BLLN vs CAI·BLLN vs GRAL
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.